Data from a Phase 3 trial of a cholesterol-lowering drug candidate developed by Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) was published in an online medical journal Friday, two weeks after an advisory committee of the U.S. Food and Drug Administration voted favorably to approve it.